Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Increases By 44.1%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 279,178 shares, a growth of 44.1% from the November 30th total of 193,734 shares. Based on an average trading volume of 227,031 shares, the days-to-cover ratio is presently 1.2 days. Approximately 19.9% of the shares of the stock are short sold. Approximately 19.9% of the shares of the stock are short sold. Based on an average trading volume of 227,031 shares, the days-to-cover ratio is presently 1.2 days.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 15th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Shuttle Pharmaceuticals presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned about 9.40% of Shuttle Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Trading Down 5.9%

Shares of SHPH traded down $0.11 during mid-day trading on Monday, hitting $1.76. 5,401 shares of the company traded hands, compared to its average volume of 173,992. The stock has a market capitalization of $2.82 million, a price-to-earnings ratio of -0.15 and a beta of -0.87. The business has a 50-day moving average of $2.16 and a 200 day moving average of $3.20. Shuttle Pharmaceuticals has a one year low of $1.26 and a one year high of $25.25.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .